Overview Services Highlights Get Started FAQs Products
mRNA-Encoded Antibody Technology
Therapeutic antibody development faces persistent challenges in manufacturing complexity and cost - barriers fundamentally addressed by mRNA-based expression systems.
At Creative Biolabs, we leverage in vivo transient translation mechanisms to enable direct cellular production of monoclonal antibodies, bispecific antibodies, and antibody fragments without plasmid integration or stable cell line development. This approach harnesses optimized nucleotide chemistry to suppress TLR-mediated immune recognition while extending functional half-life to >72 hours in target tissues. Combined with tissue-specific delivery vectors, our platform achieves sustained therapeutic antibody titers at defined pharmacokinetic windows, circumventing traditional bottlenecks in protein purification, post-translational modification control, and large-scale bioreactor dependence. This paradigm shift empowers researchers to explore dynamic antibody dosing, localized tumor microenvironments, and rapid multi-specific antibody prototyping—accelerating discovery in oncology, autoimmune disorders, and regenerative immunomodulation
Featured Services
Precision Antibody-coding mRNA Therapeutics Development
Creative Biolabs engineers species-specific antibody-coding mRNAs through AI-driven codon adaptation and structural stability prediction. Our proprietary algorithm analyzes FcγR binding affinity, Fab flexibility, and aggregation hotspots to maximize translational efficiency while minimizing truncated variants. Applications include:
-
De novo design of humanized/scFv sequences for in situ expression
-
Bispecific antibody mRNA assemblies with tuned heavy-light chain ratios
-
Immune-silent Fc variants for reduced clearance in chronic therapies
Creative Biolabs develops cell-selective LNP/exosome formulations for precise antibody mRNA delivery to lymphoid organs or solid tumors. Our platforms utilize:
-
Dendritic cell-targeting LNPs with mannose-functionalized lipids
-
Tumor-penetrating exosomes engineered with MMP-cleavable peptides
-
Lymph node-homing polymers for systemic immune cell transfection
-
Functional Validation & Potency Profiling
Creative Biolabs employs multi-omics approaches to verify antibody functionality:
-
Surface plasmon resonance (SPR) for kinetic affinity measurement
-
In vivo bioluminescence tracking of antibody distribution and persistence
Creative Biolabs pioneers mRNA-driven immune cell engineering for:
-
Generating transient CAR-macrophages via anti-CD47 antibody expression
-
Reprogramming fibroblasts into antibody-secreting cells using B-lineage transcription factors
-
Co-delivering checkpoint antibody mRNAs with tumor antigens to enhance dendritic cell vaccines
Fig.1 Collaborative Research Workflow.
Multi-Dimensional Quality Control Framework
Creative Biolabs implements integrated analytical methodologies to ensure research-grade data integrity:
-
Single-Cell Transcriptomic Verification
Characterization of transfected populations at single-cell resolution confirms target-selective antibody mRNA engagement while excluding off-target expression artifacts.
-
High-Content Secretion Profiling
Automated microfluidic chambers quantify antibody secretion kinetics and glycosylation patterns across temporal stages.
-
Microenvironmental Impact Analysis
Multiplexed cytokine arrays map immune cell activation signatures induced by locally expressed antibodies.
-
Longitudinal Biodistribution Tracking
Near-infrared tagged LNPs enable non-invasive whole-body imaging of dynamic antibody expressions.
Fig.2 Integrated Multimodal Quality Control Framework.
Related mRNA Services
Immunotherapy related mRNA Development
-
Tumor-Specific Antigen Design: Engineering neoantigen/TSA-targeting constructs
-
Immune Checkpoint Modulation: Temporally regulating PD-1/CTLA-4 pathways
-
Adoptive Cell Therapy Enhancement: Optimizing CAR/TCR/TIL functional persistence
Genetic Disease-related mRNA Development
-
Mutation Correction: Delivering functional protein variants
-
Splice-Switching: Modulating aberrant RNA processing
-
Epigenetic Reprogramming: Transiently editing chromatin states
Regenerative Medicine-related mRNA Development
-
Non-integrative Reprogramming: Generating stem/progenitor cells
-
Tissue-Specific Differentiation: Directing lineage commitment signals
-
Microenvironment Modulation: Expressing niche-supporting factors
mRNA Pharmacology Optimization
-
Delivery Vector Screening: Profiling LNP/polymer transfection efficiency
-
Immunogenicity Reduction: Engineering nucleotide/UTR modifications
-
Tissue-Specific Biodistribution: Mapping payload delivery kinetics
mRNA Vaccine Development
-
Pathogen Antigen Design: Encoding conserved/emergent immunogens
-
Adjuvant Co-Delivery: Coordinating innate immune activation
-
Cross-Reactivity Evaluation: Assessing variant strain coverage
Why Partner with Creative Biolabs?
Proprietary mRNA Engineering Architecture
-
Core Technology: AI-optimized UTR/ORF assemblies maximizing antibody folding fidelity
-
Scientific Impact: Enables expression of complex multi-chain antibodies
-
Service Edge: De novo sequence design → functional validation in 3 weeks
Cell-Type-Specific Delivery Mastery
-
Core Technology: Tissue-homing LNP/exosome platforms targeting lymphoid organs/tumors
-
Scientific Impact: Achieves localized antibody production in stromal niches
-
Service Edge: 12+ formulation screening in parallel for your unique cellular model
Mechanistic Profiling Depth
-
Core Technology: Single-cell secretion mapping + microenvironment crosstalk analysis
-
Scientific Impact: Reveals antibody-dependent bystander T cell activation
-
Service Edge: Integrated datasets replace fragmented analytical workflows
End-to-End Translational Acceleration
-
Core Technology: From sequence to biodistribution in unified platform
-
Scientific Impact: Eliminates cell line development/protein purification bottlenecks
-
Service Edge: Iterative optimization cycles reduced by 70% versus traditional approaches
Accelerate Your Antibody Discovery
Creative Biolabs transforms therapeutic antibody development through temporally controlled, tissue-localized expression systems. Our mRNA-centric approach eliminates costly cell culture infrastructure while enabling rapid iterative design—from sequence to functional validation in 6 weeks. Contact our scientific team to design your next-generation antibody project.
FAQs
Q1: How do you ensure correct heavy/light chain assembly in bispecific antibodies?
A: We engineer self-assembling mRNA scaffolds with optimized Kozak sequences and inter-chain linker ratios validated via native PAGE-MS.
Q2: Can I express membrane-bound antibodies?
A: Yes, we incorporate signal peptides and transmembrane domains with enhanced ribosomal docking efficiency.
Q3: What models validate antibody functionality?
A: Human PBMC-humanized mice, patient-derived tumor organoids, and primary immune cell cocultures.
Q4: Are your LNPs compatible with repeated dosing?
A: Stealth LNPs with CD47-mimic peptides evade macrophage clearance, supporting multi-cycle regimens.
Featured mRNA Products
Reference
-
Guo, Chipeng, et al. "Therapeutic Potential of Lipid Nanoparticle‐Encapsulated CD19‐Targeting mRNAs in Lupus and Rheumatoid Arthritis." Advanced Science (2025): 2501628. Distributed under Open Access license CC-BY 4.0, without modification. https://doi.org/10.1002/advs.202501628
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
